Laís F Berro1,2,3, Maylen Perez Diaz1,3, Eric Maltbie1,3, Leonard L Howell4,5. 1. Yerkes National Primate Research Center, Emory University, 954 Gatewood Road N.E, Atlanta, GA, 30329, USA. 2. Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, SP, Brazil. 3. Department of Psychiatry and Behavioral Science, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road N.E, Atlanta, GA, 30329, USA. 4. Yerkes National Primate Research Center, Emory University, 954 Gatewood Road N.E, Atlanta, GA, 30329, USA. lhowell@emory.edu. 5. Department of Psychiatry and Behavioral Science, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road N.E, Atlanta, GA, 30329, USA. lhowell@emory.edu.
Abstract
RATIONALE: Accumulating evidence shows that the serotonergic system plays a major role in psychostimulant abuse through its interactions with the dopaminergic system. Studies indicate that serotonin 5-HT2C receptors are one of the main classes of receptors involved in mediating the influence of serotonin in drug abuse. OBJECTIVE: The aim of the present study was to evaluate the effects of the selective serotonin 5-HT2C receptor agonist WAY163909 on the behavioral neuropharmacology of cocaine and methamphetamine in adult rhesus macaques. METHODS: Cocaine or methamphetamine self-administration and reinstatement were evaluated under second-order and fixed-ratio schedules of reinforcement, respectively. Cocaine- and methamphetamine-induced increases in dopamine were assessed through in vivo microdialysis targeting the nucleus accumbens. RESULTS: Pretreatment with WAY163909 dose-dependently attenuated cocaine and methamphetamine self-administration and drug-induced reinstatement of extinguished behavior previously maintained by cocaine or methamphetamine delivery. In an additional experiment, WAY163909 induced a dose-dependent attenuation of cocaine- or methamphetamine-induced dopamine overflow in the nucleus accumbens. CONCLUSIONS: Our data indicate that selective 5-HT2C receptor activation decreases drug intake and drug-seeking behavior in nonhuman primate models of psychostimulant abuse through neurochemical mechanisms involved in the modulation of mesolimbic dopamine.
RATIONALE: Accumulating evidence shows that the serotonergic system plays a major role in psychostimulant abuse through its interactions with the dopaminergic system. Studies indicate that serotonin5-HT2C receptors are one of the main classes of receptors involved in mediating the influence of serotonin in drug abuse. OBJECTIVE: The aim of the present study was to evaluate the effects of the selective serotonin5-HT2C receptor agonist WAY163909 on the behavioral neuropharmacology of cocaine and methamphetamine in adult rhesus macaques. METHODS:Cocaine or methamphetamine self-administration and reinstatement were evaluated under second-order and fixed-ratio schedules of reinforcement, respectively. Cocaine- and methamphetamine-induced increases in dopamine were assessed through in vivo microdialysis targeting the nucleus accumbens. RESULTS: Pretreatment with WAY163909 dose-dependently attenuated cocaine and methamphetamine self-administration and drug-induced reinstatement of extinguished behavior previously maintained by cocaine or methamphetamine delivery. In an additional experiment, WAY163909 induced a dose-dependent attenuation of cocaine- or methamphetamine-induced dopamine overflow in the nucleus accumbens. CONCLUSIONS: Our data indicate that selective 5-HT2C receptor activation decreases drug intake and drug-seeking behavior in nonhuman primate models of psychostimulant abuse through neurochemical mechanisms involved in the modulation of mesolimbic dopamine.
Entities:
Keywords:
Cocaine; In vivo microdialysis; Methamphetamine; Reinstatement; Rhesus monkeys; Self-administration
Authors: John Dunlop; Stephanie W Watts; James E Barrett; Joseph Coupet; Boyd Harrison; Hossein Mazandarani; Stanley Nawoschik; Menelas N Pangalos; Siva Ramamoorthy; Lee Schechter; Deborah Smith; Gary Stack; Jean Zhang; Guoming Zhang; Sharon Rosenzweig-Lipson Journal: J Pharmacol Exp Ther Date: 2011-03-14 Impact factor: 4.030
Authors: Catharine A Winstanley; David E H Theobald; Jeffrey W Dalley; Jeffrey C Glennon; Trevor W Robbins Journal: Psychopharmacology (Berl) Date: 2004-06-30 Impact factor: 4.530
Authors: Ramesh Neelamegam; Tim Hellenbrand; Frederick A Schroeder; Changning Wang; Jacob M Hooker Journal: J Med Chem Date: 2014-02-12 Impact factor: 7.446
Authors: Melis Odabas-Geldiay; Hannah Shields; Lais F Berro; Kenner C Rice; Leonard L Howell Journal: Drug Alcohol Depend Date: 2018-11-13 Impact factor: 4.492
Authors: Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell Journal: Exp Clin Psychopharmacol Date: 2018-06-25 Impact factor: 3.157
Authors: Paulo Cesar Ribeiro Barbosa; Luís F Tófoli; Michael P Bogenschutz; Robert Hoy; Lais F Berro; Eduardo A V Marinho; Kelsy N Areco; Michael J Winkelman Journal: Front Psychiatry Date: 2018-04-24 Impact factor: 4.157
Authors: Elisangela G Cata-Preta; Yasmim A Serra; Eliseu da C Moreira-Junior; Henrique S Reis; Natali D Kisaki; Matheus Libarino-Santos; Raiany R R Silva; Thaísa Barros-Santos; Lucas C Santos; Paulo C R Barbosa; José L Costa; Alexandre J Oliveira-Lima; Lais F Berro; Eduardo A V Marinho Journal: Front Pharmacol Date: 2018-05-29 Impact factor: 5.810
Authors: Amanda E Price; Noelle C Anastasio; Sonja J Stutz; Jonathan D Hommel; Kathryn A Cunningham Journal: Front Pharmacol Date: 2018-07-27 Impact factor: 5.810